Abstract

This is an application for the continuation of the ongoing trial """"""""African-American Antiplatelet Stroke Prevention Trial (AAASP). This is a multicenter, randomized double blind clinical trial comparing ticlopidine (500 mg/day) with aspirin (650 mg/day). The purpose is to test the efficacy of the two treatments in preventing recurrent stroke, vascular death and myocardial infarction. Patients are enrolled no more than 90 days after incident cerebral infarction and are followed for 2 years. The investigators have already recruited 1400 of the needed 1800 subjects. Dr. Gorelick and colleagues have demonstrated their ability to conduct a trial of this magnitude having overcome initial difficulties in recruitment, which require the expansion to sites outside the Chicago area. They have currently completed two-thirds of the projected enrollment and should be able to continue to administer this trial competently to its conclusion.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS033430-09
Application #
6639468
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Marler, John R
Project Start
1995-07-01
Project End
2003-12-31
Budget Start
2003-07-01
Budget End
2003-12-31
Support Year
9
Fiscal Year
2003
Total Cost
$1,233,292
Indirect Cost

  Institution

Name
Rush University Medical Center
Department
Type
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612

  Publications

Testai, Fernando D; Cursio, John F; Gorelick, Philip B (2010) Effect of sex on outcome after recurrent stroke in African Americans: results from the African American Antiplatelet Stroke Prevention Study. J Stroke Cerebrovasc Dis 19:321-5
Ruland, S; Richardson, D; Hung, E et al. (2006) Predictors of recurrent stroke in African Americans. Neurology 67:567-71
Iadecola, Costantino; Gorelick, Philip B (2005) The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke 36:182-5
Bruno, Askiel; McConnell, Joseph P; Cohen, Stanley N et al. (2005) Plasma thrombosis markers following cerebral infarction in African Americans. Thromb Res 115:73-7
Gorelick, Philip B; Weisman, Steven M (2005) Risk of hemorrhagic stroke with aspirin use: an update. Stroke 36:1801-7
Ruland, Sean; Hung, Elena; Richardson, Dejuran et al. (2005) Impact of obesity and the metabolic syndrome on risk factors in African American stroke survivors: a report from the AAASPS. Arch Neurol 62:386-90
Gorelick, Philip B (2005) William M. Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke 36:875-9
Gorelick, Philip B; Ruland, Sean (2004) IMAGES and FAST-MAG: magnesium for acute ischaemic stroke. Lancet Neurol 3:330
Gorelick, Philip B (2004) Risk factors for vascular dementia and Alzheimer disease. Stroke 35:2620-2
Iadecola, Costantino; Gorelick, Philip B (2004) Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 35:348-50

Showing the most recent 10 out of 35 publications